Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase III multicenter study.

Trial Profile

Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase III multicenter study.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2013

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms GIM-7-DOT
  • Most Recent Events

    • 28 Apr 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top